Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced HNSCC
NCT07552558Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 7 weeks and Pathologic Complete Response at 7 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07552558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07552558.